Clinical Trial Update: Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating the CAF01 liposomal adjuvant with the tuberculosis subunit vaccine Ag85B-ESAT-6 in healthy adult volunteers has completed. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Ag85B-ESAT-6 TB subunit vaccine (Tuberculosis subunit vaccine (Ag85B-ESAT-6))
• CAF01 (liposomal adjuvant system CAF01)

Snippet

Sponsor: Statens Serum Institut | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED